- POINT Biopharma Global ( NASDAQ: PNT ) has announced that it has commenced an underwritten public offering of its common stock.
- In addition, underwriters were granted a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the public offering price.
- All of the shares of common stock in this offering will be sold by POINT.
- Net proceeds will be used to fund clinical and preclinical research and development programs, pre-commercialization activities, and for working capital and other general corporate purposes.
- PNT shares -10.03% after hours to $9.15.
For further details see:
Point Biopharma plummets on announcing common stock offering